Text Size

The Effect of Reduced Dose of Enoxaparin on the Outcomes of Treatment With Enoxaparin

This study is currently recruiting participants.
Verified June 2011 by Hadassah Medical Organization
Sponsor:
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00354796
First received: July 19, 2006
Last updated: July 3, 2011
Last verified: June 2011
History of Changes
  Purpose

We hypothesize that reduced dose of enoxaparin in elderly patients will result in reduced proportion of patients with therapeutic anti Xa activity and reduced clinical efficacy.


Condition
Acute Coronary Syndrome
Venous Thromboembolism
Atrial Fibrillation
Hypercoagulability

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Effect of Reduced Dose of Enoxaparin on the Laboratory and Clinical Outcomes of Treatment With Enoxaparin

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Hadassah Medical Organization:

Estimated Enrollment: 500
Study Start Date: July 2006
Estimated Study Completion Date: October 2015
Detailed Description:

Patients treated with enoxaparin will be followed, sociodemographic , clinical and laboratory data will be collected. Clinical efficacy as well as adverse events will be monitored.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients admitted to tertiary hospital

Criteria

Inclusion Criteria:

  • treatment with enoxaparin

Exclusion Criteria:

  • no
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00354796

Contacts
Contact: Mordechai Muszkat, MD 00-972-2-6776449 muszkatm@hadassah.org.il

Locations
Israel
Hadassah Medical Organization Recruiting
Jerusalem, Israel, 91120
Contact: Arik Tzukert, DMD     00 972 2 6776095     arik@hadassah.org.il    
Contact: hadas Lemberg, PhD     00 972 2 6777572     lhadas@hadassah.org.il    
Principal Investigator: Mordechai Muszkat, MD            
Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Principal Investigator: Mordechai Muszkat, MD Hadassah University Hospital
  More Information

No publications provided

Responsible Party: Mordechai Muszkat, Hadassah University Hospital
ClinicalTrials.gov Identifier: NCT00354796     History of Changes
Other Study ID Numbers: enoxap-HMO-CTIL
Study First Received: July 19, 2006
Last Updated: July 3, 2011
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hadassah Medical Organization:
bleeding
anticoagulation
LMWH
Enoxaparin

Additional relevant MeSH terms:
Atrial Fibrillation
Thromboembolism
Thrombophilia
Acute Coronary Syndrome
Venous Thromboembolism
Venous Thrombosis
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Embolism and Thrombosis
Vascular Diseases
Thrombosis
Hematologic Diseases
 Myocardial Ischemia
Angina Pectoris
Chest Pain
Pain
Signs and Symptoms
Enoxaparin
Anticoagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents

ClinicalTrials.gov processed this record on May 23, 2013